AstraZeneca PLC
AZN
$192.17
-$0.34-0.17%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.50B | 15.19B | 14.46B | 13.59B | 14.89B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.50B | 15.19B | 14.46B | 13.59B | 14.89B |
| Cost of Revenue | 3.17B | 2.79B | 2.55B | 2.23B | 2.16B |
| Gross Profit | 12.33B | 12.40B | 11.91B | 11.36B | 12.74B |
| SG&A Expenses | 5.32B | 5.20B | 4.98B | 4.57B | 4.47B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 53.00M | -89.00M | -72.00M | -114.00M | -38.00M |
| Total Operating Expenses | 12.16B | 11.53B | 10.97B | 9.79B | 9.93B |
| Operating Income | 3.35B | 3.66B | 3.49B | 3.80B | 4.96B |
| Income Before Tax | 2.63B | 3.24B | 3.13B | 3.40B | 1.67B |
| Income Tax Expenses | 300.00M | 709.00M | 679.00M | 481.00M | 166.00M |
| Earnings from Continuing Operations | 2.33B | 2.54B | 2.45B | 2.92B | 1.50B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -3.00M | -2.00M | 2.00M | -5.00M | 0.00 |
| Net Income | 2.33B | 2.53B | 2.45B | 2.92B | 1.50B |
| EBIT | 3.35B | 3.66B | 3.49B | 3.80B | 4.96B |
| EBITDA | 4.11B | 5.21B | 4.88B | 5.08B | 5.25B |
| EPS Basic | 1.50 | 1.63 | 1.58 | 1.88 | 0.97 |
| Normalized Basic EPS | 1.23 | 1.34 | 1.25 | 1.42 | 1.87 |
| EPS Diluted | 1.48 | 1.62 | 1.57 | 1.87 | 0.96 |
| Normalized Diluted EPS | 1.22 | 1.33 | 1.25 | 1.41 | 1.86 |
| Average Basic Shares Outstanding | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B |
| Average Diluted Shares Outstanding | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B |
| Dividend Per Share | 2.17 | 0.00 | 1.03 | -- | 2.10 |
| Payout Ratio | -- | 63.60% | 0.41% | 114.78% | -- |